دورية أكاديمية
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
| العنوان: | The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. |
|---|---|
| المؤلفون: | Noble, Sian M, Garfield, Kirsty, Lane, J Athene, Metcalfe, Chris, Davis, Michael, Walsh, Eleanor I, Martin, Richard M, Turner, Emma L, Peters, Tim J, Thorn, Joanna C, Mason, Malcolm, Bollina, Prasad, Catto, James WF, Doherty, Alan, Gnanapragasam, Vincent, Hughes, Owen, Kockelbergh, Roger, Kynaston, Howard, Paul, Alan, Paez, Edgar, Rosario, Derek J, Rowe, Edward, Oxley, Jon, Staffurth, John, Neal, David E, Hamdy, Freddie C, Donovan, Jenny L |
| بيانات النشر: | Springer Science and Business Media LLC //dx.doi.org/10.1038/s41416-020-0978-4 Br J Cancer |
| سنة النشر: | 2020 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Adult, Aged, Cost-Benefit Analysis, Health Care Costs, Humans, Male, Middle Aged, Prostatic Neoplasms, Quality-Adjusted Life Years |
| الوصف: | BACKGROUND: There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer. METHODS: The cost-effectiveness of active monitoring, surgery, and radiotherapy was evaluated within the Prostate Testing for Cancer and Treatment (ProtecT) randomised controlled trial from a UK NHS perspective at 10 years' median follow-up. Prostate cancer resource-use collected from hospital records and trial participants was valued using UK reference-costs. QALYs (quality-adjusted-life-years) were calculated from patient-reported EQ-5D-3L measurements. Adjusted mean costs, QALYs, and incremental cost-effectiveness ratios were calculated; cost-effectiveness acceptability curves and sensitivity analyses addressed uncertainty; subgroup analyses considered age and disease-risk. RESULTS: Adjusted mean QALYs were similar between groups: 6.89 (active monitoring), 7.09 (radiotherapy), and 6.91 (surgery). Active monitoring had lower adjusted mean costs (£5913) than radiotherapy (£7361) and surgery (£7519). Radiotherapy was the most likely (58% probability) cost-effective option at the UK NICE willingness-to-pay threshold (£20,000 per QALY). Subgroup analyses confirmed radiotherapy was cost-effective for older men and intermediate/high-risk disease groups; active monitoring was more likely to be the cost-effective option for younger men and low-risk groups. CONCLUSIONS: Longer follow-up and modelling are required to determine the most cost-effective treatment for localised prostate cancer over a man's lifetime. TRIAL REGISTRATION: Current Controlled Trials number, ISRCTN20141297: http://isrctn.orgTest (14/10/2002); ClinicalTrials.gov number, NCT02044172: http://www.clinicaltrials.govTest (23/01/2014). |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | Print-Electronic; application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/309134Test |
| DOI: | 10.17863/CAM.56231 |
| الإتاحة: | https://doi.org/10.17863/CAM.56231Test https://www.repository.cam.ac.uk/handle/1810/309134Test |
| حقوق: | Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.8BB30B0E |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.56231 |
|---|